Abstract:Hypereosinophilia is defined as either a continuous concentration of 1.5×10 9 /L eosinophils in the blood for at least 1 month apart periods or at least 20% eosinophils on bone marrow biopsy. Hypereosinophilic syndrome (HES) is a group of blood disorders that occur when an individual has high numbers of eosinophils, and the excess eosinophils enter various tissues, eventually damaging body organs. HES is classified into primary HES, caused by myeloid neoplasms (MNs), and secondary HES, in which polyclonal expansion of eosinophils is induced by factors other than MNs. To diagnose HES, genetic tests, such as fluorescence in situ hybridization (FISH) and reverse transcription-polymerase chain reaction, which can detect targeted fusion genes, should be accompanied by chromosomal karyotyping in bone marrow aspirates. Here, we aimed to analyze the results of several genetic tests performed for diagnosing hypereosinophilia, including targeted RNA-sequencing (RNAseq). We retrospectively analyzed the information of 68 patients with suspected HES who underwent bone marrow examination from 2018 to 2022. FISH panels for eosinophilia ( FIP1L1 / PDGFRA , PDGFRB , and FGFR1 rearrangement probes(Abbott)) and chromosomal karyotyping after bone marrow aspiration and biopsy were included. RNAseq was performed to identify fusion genes or genetic variants. Targeted RNAseq was obtained for 85 genes using the panel (KblueBio), and the data was analyzed using NGeneAnalysis (NGeneBio). Among the 68 patients analyzed, 30 patients (44%) were diagnosed with reactive hypereosinophilia as the final diagnosis. Secondary HES was diagnosed in 33 patients (50%), followed by 4 patients diagnosed with primary HES including myeloid neoplasms with gene rearrangement, and one AML patient. Chromosome karyotyping was performed in 66 patients (97%), and 61 (92%) had normal karyotypes. FISH analysis was performed in 46 patients (68%), and 41 (89%) had negative results. The remaining five patients had the following results; numerical abnormality of FIP1L1 / PDGFRA , numerical abnormality of PDGFRB , numerical abnormality of 11q23, positive for FGFR1 rearrangement, and positive for FIP1L1 / PDGFRA rearrangement. Targeted RNAseq was performed in 33 patients (49%), and significant gene rearrangements were observed in 4 patients (12%). TCF3 :: JAK2 fusion was found in the patient diagnosed with HES. FGFR1 :: CNTRL , FGFR1 :: SSBP2 , and FIP1L1 :: PDGFRA fusions were found in each patient diagnosed with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes. FGFR1 :: SSBP2 fusion was not observed in FISH but only in RNAseq. To work-up for hypereosinophilia, RNAseq is considered a complementary useful test to find a clonal abnormality that can be missed in existing tests such as chromosomal karyotyping and FISH.

Imatinib is effective in some PDGFRA/B‐negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms

Phase II trial of imatinib mesylate in patients with PDGFRA/B‐negative hypereosinophilic syndrome

FIP1L1-PDGFRalpha Alone or with Other Genetic Abnormalities Reveals Disease Progression in Chronic Eosinophilic Leukemia but Good Response to Imatinib.

[Identification of FIP1L1-PDGFRA Fusion, and Expression of Signal Transducer and Activator of Transcription 5 in Hypereosinophilic Syndrome].

Successful Treatment of Myeloid Neoplasms Associated with PDGFRA Rearrangement with Imatinib Mesylate

Identification of a novel PDGFRA point mutation at p.P6L as a potential molecular target of imatinib in an eosinophilia patient showing genetic heterogeneity

[Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia].

Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders

Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report

Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases

Triptolide Abrogates Oncogene FIP1L1‐PDGFRα Addiction and Induces Apoptosis in Hypereosinophilic Syndrome

World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management

A-142 Usefulness of Targeted RNAseq to Diagnosis of Patients with Suspected hypereosinophilic syndrome: Retrospective Analysis in a single hospital

Cough in Hypereosinophilic Syndrome: Case Report and Literature Review

First-line Sintilimab Combined with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer: A Phase II Study and Post-Hoc Biomarker Analysis.

Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 plus Imatinib for Advanced Treatment-refractory Gastrointestinal Stromal Tumors

Impact of Serum Vascular Endothelial Growth Factor and Interleukin-6 on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-cell Lung Cancer

Two pediatric oncologic cases of hypereosinophilic syndrome and review of the literature

Cyclin-dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor Α and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells.

Antitumor Activity of S116836, a Novel Tyrosine Kinase Inhibitor, Against Imatinib-Resistant FIP1L1-PDGFRα-expressing Cells

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA